Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
Saved in:
| Title: | Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. |
|---|---|
| Authors: | Piccart M; Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: martine.piccart@bordet.be., Hortobagyi GN; Department of Breast Medical Oncology, Multidisciplinary Breast Cancer Research Program, University of Texas MD Anderson Cancer Center, Houston, USA., Campone M; Institut de Cancérologie de l'Ouest, René Gauducheau, Centre de Recherche en Cancérologie, Nantes Saint Herblain, France., Pritchard KI; Department of Medicine, Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Canada., Lebrun F; Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Ito Y; Department of Breast Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo., Noguchi S; Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan., Perez A; Breast Cancer Centers, Memorial Cancer Institute, Hollywood., Rugo HS; Breast Oncology and Clinical Trials Education, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA., Deleu I; Oncologic Centre, AZ Nikolaas, Sint-Niklaas, Belgium., Burris HA 3rd; Sarah Cannon Research Institute, Nashville, USA., Provencher L; Centre des Maladies du Sein Deschênes-Fabia, CHU-Hôpital du Saint Sacrement, Québec, Canada., Neven P; Multidisciplinary Breast Centre and Department of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium., Gnant M; Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria., Shtivelband M; Ironwood Cancer & Research Centers, Chandler., Wu C; Novartis Pharmaceuticals Corporation, East Hanover., Fan J; Novartis Pharmaceuticals Corporation, East Hanover., Feng W; Novartis Pharmaceuticals Corporation, East Hanover., Taran T; Novartis Pharmaceuticals Corporation, East Hanover., Baselga J; Memorial Sloan-Kettering Cancer Center, New York, USA. |
| Source: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2014 Dec; Vol. 25 (12), pp. 2357-2362. Date of Electronic Publication: 2014 Sep 17. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 25231953 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Piccart+M%22">Piccart M</searchLink>; Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: martine.piccart@bordet.be.<br /><searchLink fieldCode="AU" term="%22Hortobagyi+GN%22">Hortobagyi GN</searchLink>; Department of Breast Medical Oncology, Multidisciplinary Breast Cancer Research Program, University of Texas MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Campone+M%22">Campone M</searchLink>; Institut de Cancérologie de l'Ouest, René Gauducheau, Centre de Recherche en Cancérologie, Nantes Saint Herblain, France.<br /><searchLink fieldCode="AU" term="%22Pritchard+KI%22">Pritchard KI</searchLink>; Department of Medicine, Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Lebrun+F%22">Lebrun F</searchLink>; Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.<br /><searchLink fieldCode="AU" term="%22Ito+Y%22">Ito Y</searchLink>; Department of Breast Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo.<br /><searchLink fieldCode="AU" term="%22Noguchi+S%22">Noguchi S</searchLink>; Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Perez+A%22">Perez A</searchLink>; Breast Cancer Centers, Memorial Cancer Institute, Hollywood.<br /><searchLink fieldCode="AU" term="%22Rugo+HS%22">Rugo HS</searchLink>; Breast Oncology and Clinical Trials Education, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Deleu+I%22">Deleu I</searchLink>; Oncologic Centre, AZ Nikolaas, Sint-Niklaas, Belgium.<br /><searchLink fieldCode="AU" term="%22Burris+HA+3rd%22">Burris HA 3rd</searchLink>; Sarah Cannon Research Institute, Nashville, USA.<br /><searchLink fieldCode="AU" term="%22Provencher+L%22">Provencher L</searchLink>; Centre des Maladies du Sein Deschênes-Fabia, CHU-Hôpital du Saint Sacrement, Québec, Canada.<br /><searchLink fieldCode="AU" term="%22Neven+P%22">Neven P</searchLink>; Multidisciplinary Breast Centre and Department of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Gnant+M%22">Gnant M</searchLink>; Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.<br /><searchLink fieldCode="AU" term="%22Shtivelband+M%22">Shtivelband M</searchLink>; Ironwood Cancer & Research Centers, Chandler.<br /><searchLink fieldCode="AU" term="%22Wu+C%22">Wu C</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover.<br /><searchLink fieldCode="AU" term="%22Fan+J%22">Fan J</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover.<br /><searchLink fieldCode="AU" term="%22Feng+W%22">Feng W</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover.<br /><searchLink fieldCode="AU" term="%22Taran+T%22">Taran T</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover.<br /><searchLink fieldCode="AU" term="%22Baselga+J%22">Baselga J</searchLink>; Memorial Sloan-Kettering Cancer Center, New York, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229007735%22">Annals of oncology : official journal of the European Society for Medical Oncology</searchLink> [Ann Oncol] 2014 Dec; Vol. 25 (12), pp. 2357-2362. <i>Date of Electronic Publication: </i>2014 Sep 17. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9007735 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1569-8041 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209237534%22">09237534 </searchLink><i>NLM ISO Abbreviation: </i>Ann Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=25231953 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1093/annonc/mdu456 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 2357 Titles: – TitleFull: Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Piccart M – PersonEntity: Name: NameFull: Hortobagyi GN – PersonEntity: Name: NameFull: Campone M – PersonEntity: Name: NameFull: Pritchard KI – PersonEntity: Name: NameFull: Lebrun F – PersonEntity: Name: NameFull: Ito Y – PersonEntity: Name: NameFull: Noguchi S – PersonEntity: Name: NameFull: Perez A – PersonEntity: Name: NameFull: Rugo HS – PersonEntity: Name: NameFull: Deleu I – PersonEntity: Name: NameFull: Burris HA 3rd – PersonEntity: Name: NameFull: Provencher L – PersonEntity: Name: NameFull: Neven P – PersonEntity: Name: NameFull: Gnant M – PersonEntity: Name: NameFull: Shtivelband M – PersonEntity: Name: NameFull: Wu C – PersonEntity: Name: NameFull: Fan J – PersonEntity: Name: NameFull: Feng W – PersonEntity: Name: NameFull: Taran T – PersonEntity: Name: NameFull: Baselga J IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 12 Text: 2014 Dec Type: published Y: 2014 Identifiers: – Type: issn-electronic Value: 1569-8041 Numbering: – Type: volume Value: 25 – Type: issue Value: 12 Titles: – TitleFull: Annals of oncology : official journal of the European Society for Medical Oncology Type: main |
| ResultId | 1 |
